Literature DB >> 16889615

Significant increase of CKS1B amplification from monoclonal gammopathy of undetermined significance to multiple myeloma and plasma cell leukaemia as demonstrated by interphase fluorescence in situ hybridisation.

Hong Chang1, Joanna Yeung, Wei Xu, Yi Ning, Bruce Patterson.   

Abstract

The genetic events that lead to tumour progression in plasma cell dyscrasia are not well understood. Interphase cytoplasmic fluorescence in situ hybridisation was used to investigate the CKS1B amplification status (at 1q21) in clonal plasma cells from 123 patients: 23 monoclonal gammopathy of undetermined significance (MGUS), 75 multiple myeloma (MM) and 26 plasma cell leukaemia (PCL). While CKS1B amplification was absent in MGUS patients, such amplification (3-8 copies) was detected in 36% of newly diagnosed MM, 52% relapsed MM and 62% PCL (P < 0.001). Our results suggest that CKS1B amplification is associated with transformation from MGUS to MM and progression to PCL.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16889615     DOI: 10.1111/j.1365-2141.2006.06237.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  11 in total

1.  Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy.

Authors:  Qing Chen; Weilin Xie; Deborah J Kuhn; Peter M Voorhees; Antonia Lopez-Girona; Derek Mendy; Laura G Corral; Veronique Plantevin Krenitsky; Weiming Xu; Laure Moutouh-de Parseval; David R Webb; Frank Mercurio; Keiichi I Nakayama; Keiko Nakayama; Robert Z Orlowski
Journal:  Blood       Date:  2008-02-27       Impact factor: 22.113

2.  CKS1B nuclear expression is inversely correlated with p27Kip1 expression and is predictive of an adverse survival in patients with multiple myeloma.

Authors:  Hong Chang; Nan Jiang; Hua Jiang; Manujendra N Saha; Connie Qi; Wei Xu; Donna Reece
Journal:  Haematologica       Date:  2010-04-26       Impact factor: 9.941

Review 3.  Applying mass spectrometry based proteomic technology to advance the understanding of multiple myeloma.

Authors:  Johann Micallef; Moyez Dharsee; Jian Chen; Suzanne Ackloo; Ken Evans; Luqui Qiu; Hong Chang
Journal:  J Hematol Oncol       Date:  2010-04-07       Impact factor: 17.388

Review 4.  Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group.

Authors:  C Fernández de Larrea; R A Kyle; B G M Durie; H Ludwig; S Usmani; D H Vesole; R Hajek; J F San Miguel; O Sezer; P Sonneveld; S K Kumar; A Mahindra; R Comenzo; A Palumbo; A Mazumber; K C Anderson; P G Richardson; A Z Badros; J Caers; M Cavo; X LeLeu; M A Dimopoulos; C S Chim; R Schots; A Noeul; D Fantl; U-H Mellqvist; O Landgren; A Chanan-Khan; P Moreau; R Fonseca; G Merlini; J J Lahuerta; J Bladé; R Z Orlowski; J J Shah
Journal:  Leukemia       Date:  2012-11-21       Impact factor: 11.528

5.  Evidence for a novel mechanism for gene amplification in multiple myeloma: 1q12 pericentromeric heterochromatin mediates breakage-fusion-bridge cycles of a 1q12 approximately 23 amplicon.

Authors:  Jeffrey R Sawyer; Erming Tian; Edward Thomas; Mark Koller; Colin Stangeby; Gael Sammartino; Linda Goosen; Charles Swanson; Regina L Binz; Bart Barlogie; John Shaughnessy
Journal:  Br J Haematol       Date:  2009-09-09       Impact factor: 6.998

6.  Cks1: Structure, Emerging Roles and Implications in Multiple Cancers.

Authors:  Vinayak Khattar; Jaideep V Thottassery
Journal:  J Cancer Ther       Date:  2013-10-01

Review 7.  Different Facets of Copy Number Changes: Permanent, Transient, and Adaptive.

Authors:  Sweta Mishra; Johnathan R Whetstine
Journal:  Mol Cell Biol       Date:  2016-01-11       Impact factor: 4.272

Review 8.  The therapeutic potential of cell cycle targeting in multiple myeloma.

Authors:  Anke Maes; Eline Menu; Kim De Veirman; Ken Maes; Karin Vand Erkerken; Elke De Bruyne
Journal:  Oncotarget       Date:  2017-06-28

9.  ARNT/HIF-1β links high-risk 1q21 gain and microenvironmental hypoxia to drug resistance and poor prognosis in multiple myeloma.

Authors:  Chuan Wu; Ting Yang; Yingmin Liu; Yicheng Lu; Yanping Yang; Xiaobo Liu; Xuelian Liu; Long Ye; Yue Sun; Xue Wang; Qingchao Li; Peiyu Yang; Xiaoyuan Yu; Sujun Gao; Shaji Kumar; Fengyan Jin; Yun Dai; Wei Li
Journal:  Cancer Med       Date:  2018-06-21       Impact factor: 4.452

Review 10.  A clinical perspective on plasma cell leukemia; current status and future directions.

Authors:  Sherilyn A Tuazon; Leona A Holmberg; Omar Nadeem; Paul G Richardson
Journal:  Blood Cancer J       Date:  2021-02-04       Impact factor: 11.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.